WO2014192030A3 - An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof - Google Patents

An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof Download PDF

Info

Publication number
WO2014192030A3
WO2014192030A3 PCT/IN2014/000364 IN2014000364W WO2014192030A3 WO 2014192030 A3 WO2014192030 A3 WO 2014192030A3 IN 2014000364 W IN2014000364 W IN 2014000364W WO 2014192030 A3 WO2014192030 A3 WO 2014192030A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutically acceptable
dabigatran etexilate
acid addition
acceptable acid
Prior art date
Application number
PCT/IN2014/000364
Other languages
French (fr)
Other versions
WO2014192030A2 (en
Inventor
Ravindra Babu Bollu
Subha Velayudhan NAIR
Prasanta Kumar DALASINGH
Venkata Sunil Kumar Indukuri
Seeta Rama Anjaneyulu GORANTLA
Satyanarayana Chava
Original Assignee
Laurus Labs Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurus Labs Private Limited filed Critical Laurus Labs Private Limited
Publication of WO2014192030A2 publication Critical patent/WO2014192030A2/en
Publication of WO2014192030A3 publication Critical patent/WO2014192030A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention provides an improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof, particularly mesylate salt. The present invention also provides novel salts of intermediates of Dabigatran etexilate and their polymorphs.
PCT/IN2014/000364 2013-05-29 2014-05-29 An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof WO2014192030A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2339CH2013 2013-05-29
IN2339/CHE/2013 2013-05-29

Publications (2)

Publication Number Publication Date
WO2014192030A2 WO2014192030A2 (en) 2014-12-04
WO2014192030A3 true WO2014192030A3 (en) 2015-02-26

Family

ID=51989492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000364 WO2014192030A2 (en) 2013-05-29 2014-05-29 An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof

Country Status (1)

Country Link
WO (1) WO2014192030A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397403A (en) * 2016-08-30 2017-02-15 苏州天马精细化学品股份有限公司 Method for purifying dabigatran etexilate mesylate intermediate

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104744438A (en) * 2014-12-17 2015-07-01 烟台东诚药业集团股份有限公司 Method for synthesising and preparing dabigatran benzimidazole intermediate
CN104892576A (en) * 2015-05-27 2015-09-09 上海应用技术学院 Purification method for Dabigatran etexilate analogue intermediate
CN105153118A (en) * 2015-09-24 2015-12-16 青岛黄海制药有限责任公司 Central control method of midbody in dabigatran etexilate mesylate preparation process
CN105418587B (en) * 2015-11-30 2017-12-01 山东新华制药股份有限公司 The process for purification of dabigatran etcxilate free alkali
CN105859686B (en) * 2016-05-24 2021-10-08 浙江华海药业股份有限公司 Refining method of dabigatran etexilate free alkali
CN107686476A (en) * 2017-09-04 2018-02-13 扬子江药业集团广州海瑞药业有限公司 A kind of preparation technology of dabigatran etexilate methanesulfonate
CN108864048A (en) * 2018-07-05 2018-11-23 天方药业有限公司 A kind of preparation method of dabigatran etexilate methanesulfonate
CN111793058A (en) * 2019-04-09 2020-10-20 鲁南制药集团股份有限公司 Improved method for preparing dabigatran etexilate intermediate
WO2022198361A1 (en) * 2021-03-22 2022-09-29 天津睿创康泰生物技术有限公司 Novel crystal form of dabigatran etexilate ethyl ester hydrochloride, preparation method therefor and use thereof
CN114716411B (en) * 2022-04-29 2024-03-15 天方药业有限公司 Method for recovering and preparing dabigatran etexilate mesylate from production mother liquor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
WO2012027543A1 (en) * 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
WO2012027543A1 (en) * 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397403A (en) * 2016-08-30 2017-02-15 苏州天马精细化学品股份有限公司 Method for purifying dabigatran etexilate mesylate intermediate

Also Published As

Publication number Publication date
WO2014192030A2 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
WO2014192030A3 (en) An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
WO2016011390A8 (en) Irak4 inhibiting agents
WO2015110897A3 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
EP3186230A4 (en) Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
EP3183238A4 (en) Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
WO2013111163A3 (en) Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
EP3191455A4 (en) Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
EP3174856A4 (en) Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
WO2014041565A3 (en) Improved process for preparation of vilanterol and intermediates thereof
EP3297678A4 (en) An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
EP3517528A4 (en) Acid addition salt of benzimidazole derivative
EP2872500A4 (en) An improved process for the preparation of dabigatran etexilate mesylate and its intermediates thereof
WO2015128875A3 (en) A process for preparation of dabigatran etexilate mesylate and intermediates thereof
WO2015121877A3 (en) Polymorphs of lomitapide and its salts
HK1258964A1 (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
AU2016248025B2 (en) Polymorphs of AFATINIB and its salts and process for the preparation of quinazolinyl derivatives
WO2014049585A3 (en) Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2014068587A3 (en) An improved process for the synthesis of dabigatran and its intermediates
EP3464316A4 (en) Process for preparation of obeticholic acid
WO2014207758A3 (en) Novel polymorph of regadenoson
WO2014141294A3 (en) An improved process for the synthesis of melphalan and the hydrochloride salt
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14803633

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14803633

Country of ref document: EP

Kind code of ref document: A2